ASC as a marker for colorectal cancer

Details ASC as a marker for colorectal cancer ASC as a marker for colorectal cancer

2007-06-20

2010-12-07

Helms, Larry R. (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

C435S007100, C435S007230

Reexamination Certificate

active

07846653

ABSTRACT:
The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein ASC (apoptosis-associated speck-like protein containing a caspase-associated recruitment domain) in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a liquid sample, derived from an individual by measuring ASC in said sample. Measurement of ASC can, e.g., be used in the early detection or diagnosis of colorectal cancer.

REFERENCES:
patent: 6911306 (2005-06-01), Vertino
patent: 2004-198419 (2004-07-01), None
patent: WO 2004/057336 (2004-07-01), None
patent: WO 2004/104593 (2004-12-01), None
patent: WO 2005/040806 (2005-05-01), None
patent: WO 2006/066917 (2006-06-01), None
Yokoyama et al, Cancer Lett, vol. 202, p. 101-108, 2003.
Bhatavdekar et al , Dis Colon Rectum vol. 44, p. 523-533, 2001.
Ahlquist, D. et al., “Fecal Occult Blood Testing for Colorectal Cancer,” Colorectal Neoplasia, Part II: Diagnosis & Treatment, vol. 26, No. 1, Mar. 1997, 41-55.
Conway, K. et al., “TMSI, a Novel Proapoptoticf Caspase Recruitment Domain Protein, Is a Target of Methylation-induced Gene Silencing in Human Breast Cancers,” Cancer Research 60, 6236-6242, Nov. 15, 2000.
Duffy, M. et al., “Clinical Utility of Biochemical Markers in Colorectal Cancer: European Group on Tumour Markers (EGTM) Guidelines,” European Journal of Cancer 49 (2003) 718-727.
Martell, R. et al., “OVX1 and CEA in Patients with Colon Carcinoma, Colon Polyps and Benign Colon Disorders,” The International Journal of Biological Markers, vol. 13, No. 3, (1998) 145-149.
Masumoto, J. et al., “ASC, a Novel 22-kDa Protein, Aggregates during Apoptosis of Human Promyelocytic Leukemia HL-60 Cells,” The Journal of Biological Chemistry, col. 274, No. 48, Nov. 26, 1999, 33835-33838.
Masumoto, J. et al., “Expression of Apoptosis-associated Speck-like Protein Containing a Caspase Recruitment Domain, a Pyrin N-terminal Homology Domain-containing Protein, in Normal Human Tissues,” The Journal of Histochemistry and Cytochemistry, vol. 49(10) 1269-1275, 2001.
Nakata, B. et al., “Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer,” British Journal of Cancer (2004) 91, 873-878.
Shiohara, M. et al., “ASC, Which is Composed of a Pyrin-N-Terminal Homology Domain and a Caspase-Recruitment Domain, Is Up-Regulated by Inflammation and Apoptosis in Human Neutrophis,” Blood, 98(2000) 229a.
Silvis, S. et al., “Endoscopic Complications,” JAMA, Mar. 1, 1976, vol. 235, No. 9, 928-930.
Sturgeon, C. et al., “Practice Guidelines for Tumor Marker Use in the Clinic,” Clinical Chemistry 48:8, 1151-1159 (2002).
Can der Gaast, A. et al., ,,Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1, Br. J. Cancer (1994) 69, 525-528.
Yokoyama, T. et al., “Methylation of ASC/TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer,” Cancer Letters 202 (2003) 101-108.
Zweig, M. et al., “Receiver-Operating Characteristics (ROC) Plots: A Fundamental Evaluation Tool in Clinical Medicine,” Clin, Chem. 39/4, 561-577 (1993).
Database UniProt (Online), EBI accession No. UNIPROT: Q9ULZ3, XP002365772, Oct. 16, 2001.
Notice of Grounds for Rejection (English Translation) of an Office Action issued Apr. 26, 2010 in Japanese Patent Application No. 2007-544847.
Kojima, Osamu et al., Igan, Daichogan Kanja ni okeru Kessei NSE no Shuyou Ma-ka- toshiteno Igi (Significance of Serum NSE Levels as Tumor Markers in Patients with Gastric and Colorectal Cancer), Rinsho Byori, 1986, pp. 1236-1240, vol. 34, No. 11, Japan.
Matsumoto, H. et al., Daichogan no Shuyokanryujomyakuketsu ni okeru CYRA21-1 Sokutei no Rinshoteki Igi—Tokuni Jutsugokekkoseisaihatsu no Koukiken-Inshi to shiteno Igi- (Clinical Significance of CYRA21-1 Assay in Mesenteric Veins of Colorectal Cancer—Particularly Significance as a High Risk Factor for Postoperative Hematogenous Metastasis-), Journal of Japan Society of Coloproctology, 2002, pp. 136-144, vol. 55, No. 3 , Japan (Abstract).
Miyashita, T. et al., Daichogan ni okeru Kessei CEA, CA19-9, CYFRA21-1, IAP Sokutei ni yoru combination assay no Rinshoteki Igi (Clinical Significance of Combination Assay of Serum CEA, CA19-9, CYFRA21-1, and IAP in Colorectal Cancer), Journal of the Japan Society of Coloproctology, 2000, pp. 76-82, vol. 53, No. 2.

Affiliated with

Also associated with

Rating

ASC as a marker for colorectal cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with ASC as a marker for colorectal cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ASC as a marker for colorectal cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4209483